Corbus Pharmaceuticals (CRBP) PT Raised to $58 at Oppenheimer
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 11/4/2026
- Wall St futures jump as Democrats sweep midterms
- CVS Health plans to split into two public companies by 2028
- UBS starts bullish coverage on Ferrari Group on luxury logistics growth
- Citi cuts Adobe rating on ’rising risk of a hard reset’
- Apple shares slip amid guidance for tightening margins, slowing services growth
Tweet
Share
E-mailGet Alerts CRBP Hot Sheet
Price: $3.87 --0%
Rating Summary:
12 Buy, 2 Hold, 0 Sell
Rating Trend:
Up
Today's Overall Ratings:
Up: 15 | Down: 20 | New: 12
Rating Summary:
12 Buy, 2 Hold, 0 Sell
Rating Trend:
Up
Today's Overall Ratings:
Up: 15 | Down: 20 | New: 12
Join SI Premium – FREE
Oppenheimer analyst Jeff Jones raised the price target on Corbus Pharmaceuticals (NASDAQ: CRBP) to $58.00 (from $51.00) while maintaining a Outperform rating.
You May Also Be Interested In
- Citi Downgrades Bank Rakyat Indonesia Persero Tbk PT (BBRI:IJ) (BKRKF) to Neutral
- Bank Negara Indonesia (BBNI:IJ) (PTBRY) PT Lowered to IDR4,200 at Citi
- Gujarat Fluorochemicals Ltd (FLUOROCH:IN) PT Raised to INR5,100 at Axis Capital Limited
Create E-mail Alert Related Categories
Analyst PT ChangeSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
